Manchester University NHS Foundation Trust

Three lupus patients in the UK received CAR T-cell therapy, a groundbreaking treatment that could potentially cure the disease and eliminate the need for lifelong drugs. The therapy, previously used in cancer patients, involves genetically modifying cells to enable the immune system to recognize and attack problem cells. Early indications suggest the therapy could revolutionize lupus treatment, with patients in Germany already showing remission without lupus drugs.

CAR T-cell therapy, traditionally used in cancer, is being trialed in the UK for lupus and multiple sclerosis. The therapy modifies immune cells to target problem cells, potentially offering a cure. Early indications suggest it could revolutionize treatment, eliminating the need for lifelong medication. Patients in Germany have shown remission without lupus drugs after CAR T-cell therapy. The UK trial, led by UCLH and UCL, has treated three lupus patients, with early positive signs.

Tunde Oremulé, ENT Registrar at Royal Manchester Children’s Hospital, highlights how teamwork accelerated the ACCENTUATE study, investigating telemedicine for children with ear issues. The study aims to reduce waiting times and improve access to ear healthcare. Rapid recruitment of healthy volunteers enabled focus on community recruitment for children with glue ear, supported by MFT and various research bodies. The study aims to complete within 12 months.